We recently completed a major investment in equipping and accrediting a new cGMP facility in order to move formulations into pilot scale production and manufacture of clinical trial materials / clinical supplies for our clients. The facility received its MIAIMP Licence from the MHRA in November 2013.
The MIAIMP GMP Licence allows MedPharm to support Phase I and II clinical manufacture (including using compounds up to OEB 4 level) with a manufacturing batch scale of up to 50 Kg. This is in addition to ICH stability testing, quality control, in vitro and ex vivo performance testing services, primary packaging, labelling and randomisation services already offered by the company.
Back to News